Ariceum Therapeutics
PrivateLast Round
Series A
Extension
Apr 18, 2023
Total Funding Raised
$51.73M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ariceum Therapeutics is a biotechnology company that develops targeted radiopharmaceutical therapies for the diagnosis and treatment of aggressive and hard-to-treat cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ariceum Therapeutics Comparables
Compare Ariceum Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alpha-9 Oncology | 83% | |
| ARTBIO | 81% | |
| Fulllife | 81% |
Ariceum Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Apr 18, 2023 | ||||
| Series A | Jun 8, 2022 |
Key People
Founding team and executive leadership
Ariceum Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A |
| Andera Partners | Series A Extension |
| HealthCap | Series A |
| Pureos Bioventures | Series A Extension, Series A |
| Earlybird Venture Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors grew 150% MoM, from 258 to 646.
- Oct 14, 2025
ATT001, a novel radiolabeled I-123 PARP inhibitor, is in development.
Ariceum Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ariceum Therapeutics's valuation, stock price, and market status.
Is Ariceum Therapeutics a public or private company?
Ariceum Therapeutics is a private company.
What is the current stock price of Ariceum Therapeutics?
Ariceum Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Ariceum Therapeutics worth (valuation)?
Valuation information for Ariceum Therapeutics is not publicly available.
Can I buy Ariceum Therapeutics stock?
Ariceum Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ariceum Therapeutics's last funding round?
Ariceum Therapeutics's most recent funding round was Series A Extension on April 18, 2023.
Who are the main investors in Ariceum Therapeutics?
Key investors in Ariceum Therapeutics include EQT Life Sciences, Andera Partners, HealthCap, Earlybird Venture Capital.
Will Ariceum Therapeutics IPO soon?
No public IPO plans have been announced for Ariceum Therapeutics.
How can I track Ariceum Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ariceum Therapeutics's secondary market activity and sign up for updates.